Renal Diseases Market Reports Empesis on Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease

The Frontier Pharma: Renal Diseases High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes.

Pune, India - March 14, 2018 /MarketersMedia/ —

The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertension and diabetes, two major causes of CKD. For most forms of renal diseases, early detection and management may slow down or prevent progression to renal failure and associated complications. However, many renal diseases are typically asymptomatic until they have progressed to end-stage renal disease (ESRD), which requires renal replacement therapies such as hemodialysis and renal transplantation, and is associated with substantial morbidity and mortality.

Access Report Details at:

The first-in-class programs identified show considerable diversity, and the relatively high degree of innovation in the renal diseases therapy area makes for a promising development pipeline. It is clear that recent activity in this area has increased, partly owing to the growing recognition of the unmet medical need. Further investment in innovation would benefit the therapy area greatly, and likely prove a worthwhile investment, particularly for highly prevalent diseases such as CKD and diabetic nephropathy, for which there are a lack of effective pharmacotherapeutic options.

Get this report at:

• With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
• There are 100 first-in-class products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
• The majority of first-in-class products were in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
• A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Inquire for more details at:

Contact Info:
Name: Shirish Gupta
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL:

For more information, please visit

Source: MarketersMedia

Release ID: 314328

More Press Releases

World markets roiled by rising fears of US-China trade war

Mar 23, 2018

HONG KONG — Fears of a trade war roiled financial markets and sent the dollar wobbling Friday after Beijing retaliated against the Trump administration's tariff hikes by threatening import duties on U.S. goods. Stocks plunged on Wall Street after U.S. President Donald Trump imposed sanctions Thursday on goods and investment from China. The Dow Jones industrial average dropped more than 700 points as investors feared trade tensions between the world's largest economies would escalate. That fear rippled into Europe. In early trading, Germany's DAX slid 1.3 percent to 11,941.68, France's CAC 40 lost 1.3 percent to 5,101.63 and Britain's FTSE...

China may hike tariffs on US pork, aluminum, other goods

Mar 23, 2018

BEIJING — China announced a $3 billion list of U.S. goods including pork, apples and steel pipe on Friday that it said may be hit with higher tariffs in a spiraling trade dispute with President Donald Trump that companies and investors worry could depress global commerce. The Commerce Ministry urged Washington to negotiate a prompt settlement to the conflict over Trump's tariff hike on steel and aluminum but set no deadline. Separately, the ministry also criticized Trump's decision to approve a possible tariff hike on billions of dollars of Chinese goods in a dispute over Beijing's technology policy. The ministry...

Asian shares slump on fears of trade war between US, China

Mar 23, 2018

HONG KONG — Asian stock markets slumped Friday after Beijing responded to the Trump administration's tariff hikes by saying it may order higher import duties on a range of U.S. goods, ratcheting up fears of a trade war. Stocks plunged Thursday on Wall Street after U.S. President Donald Trump imposed sanctions on goods and investment from China. The Dow Jones industrial average dropped more than 700 points as investors feared that trade tensions between the world's largest economies would escalate. The planned sanctions include tariffs on $48 billion worth of Chinese imports as well as restrictions on Chinese investments. Trump...

Venezuela president solution to inflation: Change money

Mar 23, 2018

CARACAS, Venezuela — President Nicolas Maduro attempted to tackle Venezuela's staggering inflation Thursday by lopping three zeros off the increasingly worthless currency called the bolivar. New bills replacing those like the current 100,000 note — worth less than 50 U.S. cents on the commonly used black market — should begin circulating June 4, he said. The move comes as Venezuelans struggle to find food, medicine and cash in the worst economic crisis ever to strike the oil-rich country. "Let's defend our bolivar!" Maduro said in a state television broadcast. He said the "redenomination" will relieve the cash shortages. Venezuela holds...

As US gets tough with China, Wall Street gets weak-kneed

Mar 23, 2018

NEW YORK — The prospect of a full-blown trade war between the world's two biggest economies rattled investors Thursday, sending stocks to their biggest loss in six weeks. The Dow Jones industrial average plunged more than 700 points, as President Donald Trump announced plans to slap tariffs on Chinese imports. The Chinese government vowed to defend itself. Investors worried that if the dispute escalated, China will counterpunch with restrictions of its own, hurting American exports of airplanes, construction equipment and other goods. It didn't take long for China to threaten to hit back. The Commerce Ministry announced a list of...

Subscribe to our newsletter!

Your Name

Your Email Address